Orbital cellulitis medical therapy

Orbital cellulitis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Orbital cellulitis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Orbital cellulitis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Orbital cellulitis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Orbital cellulitis medical therapy
CDC on Orbital cellulitis medical therapy
Orbital cellulitis medical therapy in the news
Blogs on Orbital cellulitis medical therapy
Directions to Hospitals Treating Orbital cellulitis
Risk calculators and risk factors for Orbital cellulitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]; Tarek Nafee, M.D. [3]

Overview

Orbital cellulitis is considered an ophthalmologic emergency. The mainstay of therapy for orbital cellulitis involves prompt intravenous antimicrobial therapy with either beta-lactams or clindamycin. Patients suspected to have MRSA-induced orbital cellulitis require more extensive antimicrobial therapy.

Medical Therapy

Antimicrobial Regimens

• 1. Causative pathogens

• Methicillin-sensitive staphylococcus aureus
• Methicillin-resistant staphylococcus aureus
• Staphylococcus epidermidis
• Streptococcus spp.
• Moraxella spp.
• Anaerobes

• 2. Empiric antimicrobial therapy

• Preferred regimen (1): Ampicillin/Sulbactam 3 g IV q6h for 1 week
• Preferred regimen (2): Ceftriaxone 1-2 g IV q12h for 1 week
• Preferred regimen (3): Clindamycin 300 mg IV q6h for 1 week
• Preferred regimen (4): Nafcillin 2 g IV q4h for 1 week AND Ceftriaxone 2 g IV q24h for 1 week AND Metronidazole 30-35 mg/kg/d IV divided in 3 doses for 1 week
• Alternative regimen (1), MRSA suspicion: Vancomycin 1 g IV q12h for 1 week AND Ceftriaxone 2 g IV q24h for 1 week AND Metronidazole 30-35 mg/kg/d IV divided q8h for 1 week
• Alternative regimen (2), MRSA suspicion: Vancomycin 1 g IV q12h for 1 week AND Levofloxacin 750 mg IV q24h for 1 week AND Metronidazole 30-35 mg/kg/d IV divided q8h for 1 week
• Alternative regimen (3), pediatric: Ampicillin/Sulbactam 200-300 mg/kg/d IV divided q6h for 1 week
• Alternative regimen (4), pediatric: Ceftriaxone 100 mg/kg/d IV divided q12h for 1 week
• Alternative regimen (5), pediatric: Clindamycin 20-40 mg/kg/d IV divided q12 for 1 week
• Note (1): Oral antibiotic therapy may be extended beyond 2-3 weeks if the clinical presentation is consistent with either severe sinusitis or bony destruction
• Note (2): Consider surgical intervention if the patient has either visual loss, complete ophthalmoplegia, large abscess > 1 cm, or no clinical improvement following 1-2 days of antibiotic administration

• 3. Pathogen-directed antimicrobial therapy

• 3.1 Methicillin-resistant staphylococcus aureus (MRSA)

• Preferred regimen (1): Vancomycin 1 g IV q12h for 1 week AND Ceftriaxone 2 g IV q24h for 1 week AND Metronidazole 30-35 mg/kg/d IV divided q8h for 1 week
• Preferred regimen (2): Vancomycin 1 g IV q12h for 1 week AND Levofloxacin 750 mg IV q24h for 1 week AND Metronidazole 30-35 mg/kg/d IV divided q8h for 1 week

• 3.2 Non-MRSA organisms

• Preferred regimen (1): Ampicillin/Sulbactam 3 g IV q6h for 1 week
• Preferred regimen (2): Ceftriaxone 1-2 g IV q12h for 1 week
• Preferred regimen (3): Clindamycin 300 mg IV q6h for 1 week
• Preferred regimen (4): Nafcillin 2 g IV q4h for 1 week AND Ceftriaxone 2 g IV q24h for 1 week AND Metronidazole 30-35 mg/kg/d IV divided in 3 doses for 1 week